Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glofitamab + golcadomide
- Development stage
- Phase 1
- Lead developer
- Genentech
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Glofitamab + golcadomide is a combination regimen under investigation for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL). Glofitamab is a bispecific monoclonal antibody that engages T cells by binding to CD3 on T cells and CD20 on B cells, thereby directing cytotoxic T cells to kill malignant B cells. Golcadomide is an oral immunomodulatory imide drug (iMiD) that binds cereblon, modulating the activity of the E3 ubiquitin ligase complex, resulting in degradation of transcription factors that regulate both immune responses and tumor cell survival. Together, the combination is being evaluated for enhanced antitumor efficacy via dual immune activation and direct tumor cell targeting, targeting both immune evasion and tumor growth[2][5].
- Other names
- glofitamab + golcadomide
02
Targets
Beyond the preview
Go deeper on glofitamab + golcadomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glofitamab + golcadomide.